No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ANIX240621C2500
- 0.15
- -0.14-48.28%
15min DelayClose Jun 18 15:59 ET
0.15High0.15Low
0.15Open0.29Pre Close1 Volume11 Open Interest2.50Strike Price15.00Turnover204.83%IV7.29%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.5048Delta0.9740Gamma16.47Leverage Ratio-0.0389Theta0.0001Rho8.31Eff Leverage0.0008Vega
Intraday
- 5D
- Daily
News
Anixa Biosciences(ANIX.US) Director Buys US$10,720 in Common Stock
$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 4,000 shares of common stock on Jun 14, 2024 at an average price of $2.68 for a total value of $10,720.Source: Announcement What is
Anixa Biosciences(ANIX.US) Director Buys US$1,093.5 in Common Stock
$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 405 shares of common stock on Jun 13, 2024 at an average price of $2.7 for a total value of $1,093.5.Source: Announcement What is s
Anixa Biosciences(ANIX.US) Director Buys US$19,749.32 in Common Stock
$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 7,432 shares of common stock on Jun 10, 11, 2024 at an average price of $2.66 for a total value of $19,749.32.Source: Announcement
Anixa Biosciences(ANIX.US) Director Buys US$27,059.76 in Common Stock
$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 10,738 shares of common stock on Jun 7, 2024 at an average price of $2.52 for a total value of $27,059.76.Source: Announcement What
Anixa Biosciences Is Maintained at Buy by HC Wainwright & Co.
Anixa Biosciences Is Maintained at Buy by HC Wainwright & Co.
Anixa Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/10/2024 169.23% HC Wainwright & Co. $12 → $7 Maintains Buy 03/21/2024 361.54% HC Wainwright & Co. → $12
Comments
Anixa Biosciences: Current Developments and Future Prospects.
On Monday, H.C. Wainwright & Co. adjusted its outlook on Anixa Biosciences (NASDAQ: ANIX) shares, reducing the 12-month price target to $7.00 from the previous $12.00 while maintaining a Buy rating. This adjustment is based on a recent financial report and a new partnership focused on cancer vaccine development. $Anixa Biosciences(ANIX.US$
https://stockregion.app/p/prominent-investment-bank-maintains
On Monday, H.C. Wainwright & Co. adjusted its outlook on Anixa Biosciences (NASDAQ: ANIX) shares, reducing the 12-month price target to $7.00 from the previous $12.00 while maintaining a Buy rating. This adjustment is based on a recent financial report and a new partnership focused on cancer vaccine development. $Anixa Biosciences(ANIX.US$
https://stockregion.app/p/prominent-investment-bank-maintains
$Anixa Biosciences(ANIX.US$
NEWS
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has commenced treatment of the fifth patient in its Phase 1 clinical trial for CAR-T therapy targeting ovarian cancer. This trial, conducted in partnership with Moffitt Cancer Center, enrolls female patients with recurrent ovarian cancer unresponsive to at least two prior therapies. The trial aims to identify the maximum tolerated dose of T-cells targe...
NEWS
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has commenced treatment of the fifth patient in its Phase 1 clinical trial for CAR-T therapy targeting ovarian cancer. This trial, conducted in partnership with Moffitt Cancer Center, enrolls female patients with recurrent ovarian cancer unresponsive to at least two prior therapies. The trial aims to identify the maximum tolerated dose of T-cells targe...
$Anixa Biosciences(ANIX.US$
NEWS
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
NEWS
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
Read more